1. Secondary Prevention in Patients With ACS and Diabetes: How Can We Optimize Therapy?

2. Panelists

3. Learning Objectives

4. Learning Objectives

5. Diabetes as a CV Risk Factor

6. Impact of Gluco-Metabolic Characteristics on Risk of Major Cardiovascular Events

9. Risk Factors in Patients With T2D After ACS

10. The HDL Hypothesis

11. Meta-analysis of Intensive Statin Trials: Coronary Death or Myocardial Infarction

12. Intensive Glucose Control in Critically Ill Patients: Death From Any Cause

14. UKPDS: Extended Follow-up Benefits of Glycemic Control

16. Comparison of CETP Inhibitors

17. DAL-OUTCOMES: 3 Years

18. AIM-HIGH: End Point at 36-month Follow-up

19. ACCORD Lipid: Hazard Ratios for the Primary Outcome

20. SYNCHRONY: Effect of Aleglitazar on Cardiometabolic Parameters in T2D

21. AleCardio: Aleglitazar in Patients With T2D and ACS

22. Unmet Needs: Diabetes in Post-ACS Patients

23. Abbreviations

24. Abbreviations (cont)

25. Abbreviations (cont)

26. References

27. References (cont)

28. References (cont)

29. References (cont)